The science, economics, and effectiveness of combination therapy for hepatitis C

Gut

Volumn 47, Issue 2, 2000, Pages 159-161

  Dusheiko, G ^a   Barnes, E ^a   Webster, G ^a   Whalley, S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; MACROGOL; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ANEMIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; EDITORIAL; HEALTH ECONOMICS; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0033930197     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.2.159     Document Type: Editorial

References (20)